Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Striatal Acetylcholine–Dopamine Imbalance in Parkinson Disease: In Vivo Neuroimaging Study with Dual-Tracer PET and Dopaminergic PET–Informed Correlational Tractography

Carlos A. Sanchez-Catasus, Nicolaas I. Bohnen, Nicholas D’Cruz and Martijn L.T.M. Müller
Journal of Nuclear Medicine March 2022, 63 (3) 438-445; DOI: https://doi.org/10.2967/jnumed.121.261939
Carlos A. Sanchez-Catasus
1Division of Nuclear Medicine, Department of Radiology, University of Michigan Health System, Ann Arbor, Michigan;
2Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands;
3Morris K. Udall Center of Excellence for Parkinson’s Disease Research, University of Michigan, Ann Arbor, Michigan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolaas I. Bohnen
1Division of Nuclear Medicine, Department of Radiology, University of Michigan Health System, Ann Arbor, Michigan;
3Morris K. Udall Center of Excellence for Parkinson’s Disease Research, University of Michigan, Ann Arbor, Michigan;
4Department of Neurology, University of Michigan Health System, Ann Arbor, Michigan;
5Neurology Service and GRECC, Veterans Administration Ann Arbor Healthcare System, Ann Arbor, Michigan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas D’Cruz
6Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martijn L.T.M. Müller
1Division of Nuclear Medicine, Department of Radiology, University of Michigan Health System, Ann Arbor, Michigan;
3Morris K. Udall Center of Excellence for Parkinson’s Disease Research, University of Michigan, Ann Arbor, Michigan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    (A) Nigrostriatal dopaminergic white matter tracts identified in PD group in MA and least affected hemispheres (overlaid on T1-weighted MR image in Montreal Neurologic Institute space). (B) Voxel-based correlation analysis showing negative correlation between mean QA of MA tract and 18F-FEOBV DVR in posterior putamen of same hemisphere. (C) Negative correlation between mean QA of MA tract and mean 18F-FEOBV DVR within putaminal SPM-based VOI (95% CI, −0.76 to −0.2). (D) Significantly higher mean 18F-FEOBV DVR within that putaminal VOI in PD group than in healthy control (NC) group.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    (A) Relation between training (predicted values) and cross-validation (observed values) sets using LOO approach (mean QA and mean QA-LOO, respectively) in MA hemisphere of PD subjects. (B) Same as shown in A, but for VOI model derived from SPM voxel-based correlation analysis (VOI and VOI-LOO, respectively). (C) Negative correlation between mean QA-LOO of MA tract and mean 18F-FEOBV DVR within VOI-LOO (95% CI, −0.75 to −0.09). (D) Significantly higher mean 18F-FEOBV DVR within VOI-LOO in PD group than in healthy control (NC) group. NRMSE = normalized root-mean-square error.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Negative correlation between mean 18F-FEOBV DVR within significant cluster correlated with mean QA in MA hemisphere (Fig. 1B) and ipsilateral whole striatum11C-DTBZ DVR (95% CI, −0.55 to −0.02).

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Voxel-based group comparison showing asymmetric bilateral putaminal 18F-FEOBV DVR increases (more extensive in MA hemisphere [left]), compared with control group (Table 2). There is partial topographic overlap of MA side with results of voxel-based correlation analysis in PD group (Fig. 1B, z = 6–4 mm [left]).

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    (A) Positive correlation between bradykinesia subscore and proxy measure of acetylcholine–dopamine imbalance in MA hemisphere in subjects with PD (95% CI, 0.15–0.62). (B) Same as shown in A, but using measures derived from LOO cross-validation analysis (95% CI, 0.07–0.59). (C) Negative correlation between bradykinesia subscore and mean QA in MA hemisphere (95% CI, −0.63 to −0.01). (D) Positive correlation between bradykinesia subscore and mean 18F-FEOBV DVR within putaminal SPM-based VOI in MA hemisphere (95% CI, 0.1–0.58).

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Demographic and Clinical Characteristics of PD and Control Subjects

    CharacteristicPD (n = 45)Control (n = 15)Statistical significance
    Age (y)66.3 ± 6.369.1 ± 8.6t = 1.3; P = 0.19
    Sexχ2 = 2.4; P = 0.12
     Male369
     Female96
    Handednessχ2 = 0.25; P = 0.62
     Right4113
     Left42
    MoCA27.0 ± 2.627.6 ± 1.8t = 0.87; P = 0.39
    MDS-UPDRS
     Part I5.1 ± 4.5
     Part II5.5 ± 3.5
     Part III34.3 ± 13.2
    Bradykinesia subscore*11.6 ± 5.9
    Tremor subscore*8.8 ± 4.4
    Rigidity subscore*7.5 ± 2.9
    PIGD subscore*2.5 ± 2
    MDS-UPDRS (I–III) total score44.9 ± 16.8
    Hoehn and Yahr stage2.2 ± 0.6 (median, 2.5; range, 1–3)
    Disease duration (y)5.8 ± 3.6
    Levodopa equivalent dose (mg)636.6 ± 374.5
    • *Derived from MDS-UPDRS (part III).

    • MoCA = Montreal cognitive assessment; MDS-UPDRS = Movement Disorder Society revised unified Parkinson disease rating scale; PIGD = postural instability and gait difficulties.

    • View popup
    TABLE 2

    Striatal Cholinergic Binding Increase in PD Group Compared with Control Group

    Striatal regionPCluster sizeMontreal Neurologic Institute coordinates (x, y, z) of maximum peakPeak-level t value
    MA putamen0.028369 voxels−32, −8, 53.93
    Least affected putamen0.043188 voxels32, −9, 64.15
    • P value is corrected for multiple comparisons at cluster level by using familywise error approach.

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (3)
Journal of Nuclear Medicine
Vol. 63, Issue 3
March 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Striatal Acetylcholine–Dopamine Imbalance in Parkinson Disease: In Vivo Neuroimaging Study with Dual-Tracer PET and Dopaminergic PET–Informed Correlational Tractography
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Striatal Acetylcholine–Dopamine Imbalance in Parkinson Disease: In Vivo Neuroimaging Study with Dual-Tracer PET and Dopaminergic PET–Informed Correlational Tractography
Carlos A. Sanchez-Catasus, Nicolaas I. Bohnen, Nicholas D’Cruz, Martijn L.T.M. Müller
Journal of Nuclear Medicine Mar 2022, 63 (3) 438-445; DOI: 10.2967/jnumed.121.261939

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Striatal Acetylcholine–Dopamine Imbalance in Parkinson Disease: In Vivo Neuroimaging Study with Dual-Tracer PET and Dopaminergic PET–Informed Correlational Tractography
Carlos A. Sanchez-Catasus, Nicolaas I. Bohnen, Nicholas D’Cruz, Martijn L.T.M. Müller
Journal of Nuclear Medicine Mar 2022, 63 (3) 438-445; DOI: 10.2967/jnumed.121.261939
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Postsynaptic adaptations in direct pathway muscarinic M4-receptor signaling follow the temporal and regional pattern of dopaminergic degeneration
  • A mismatch between striatal cholinergic pauses and dopaminergic reward prediction errors
  • Ca2+-dependent phosphodiesterase 1 regulates the plasticity of striatal spiny projection neuron glutamatergic synapses
  • M4-mediated cholinergic transmission is reduced in parkinsonian mice and its restoration alleviates motor deficits and levodopa-induced dyskinesia
  • Google Scholar

More in this TOC Section

  • SNMMI Procedure Standard/EANM Practice Guideline for Brain [18F]FDG PET Imaging, Version 2.0
  • Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein–Targeted Imaging—FAP-RADS Version 1.0
  • Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study
Show more Clinical Investigation

Similar Articles

Keywords

  • Parkinson disease
  • acetylcholine–dopamine imbalance
  • dopaminergic nigrostriatal connectivity
  • 18F-FEOBV PET
  • 11C-DTBZ PET
SNMMI

© 2025 SNMMI

Powered by HighWire